SinfrasSinfras
Aa
  • Home
  • Diet
  • Gadgets
  • Sports
  • Education
  • Social Media
  • Clothing
  • News
  • Contact Us!
  • Privacy Policy
Reading: This new HIV therapy could boost immunity levels in patients
Share
Aa
SinfrasSinfras
Search
  • Home
  • Diet
  • Gadgets
  • Sports
  • Education
  • Social Media
  • Clothing
  • News
  • Contact Us!
  • Privacy Policy
Have an existing account? Sign In
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Sinfras > Diet > This new HIV therapy could boost immunity levels in patients
Diet

This new HIV therapy could boost immunity levels in patients

Loknath Das
Last updated: 2018/08/20 at 5:38 AM
By Loknath Das 2 Min Read
Share

HIV,HIV treatment,HIV and immunity

Turns out, a new HIV drug can reduce the viral replication and increase immune cells in individuals with advanced, drug-resistant HIV infection.

Used in combination with existing HIV medications, the drug is a promising strategy for patients who have run out of effective treatment options, the researchers at Yale University said.

For some individuals with HIV, existing drug therapies fail to suppress the virus, leading to drug resistance and worsening disease. While several HIV drugs target the virus effectively, there has not been a new class of HIV drugs approved to combat the disease in a decade.

During the study, patients received a dose of ibalizumab, which is delivered intravenously, in addition to their failing regimen, for one week. After that period, they received ibalizumab in combination with optimized treatment regimens for six months.

The research team found that after one week on ibalizumab, the majority of the 40 patients (83%) enrolled in the study experienced a decrease in viral load, which refers to the amount of HIV detected in the blood. After 25 weeks, nearly half of patients saw viral load suppression dip below the level of detection. The researchers also reported an increase in CD4 T cells, which are a marker for immune strength. A single individual experienced an adverse event, which was felt to be ibalizumab-related and resulted in withdrawal from the study, the researchers said.

As the first monoclonal antibody approved to treat HIV, ibalizumab is a promising option for individuals who have tried several other drug therapies.

Because of its novel mechanism, ibalizumab will not interact negatively with other medications. It is also delivered intravenously every two weeks and lasts longer than current HIV drugs, which are taken daily by mouth.

The findings appeared in the New England Journal of Medicine.

 

 

[“source=hindustantimes”]

Share this:

  • Click to share on Reddit (Opens in new window) Reddit
  • Tweet
  • Share on Tumblr
  • Click to share on WhatsApp (Opens in new window) WhatsApp
TAGGED: 'could, Boost, HIV, Immunity, in, Levels, New, patients, therapy, This
Loknath Das August 20, 2018
By Loknath Das
I am a blogger with the main motive of writing articles at my choice of level. I do love to write articles and keep my website updated regularly , if you love my article then be sure to share with your friends as they would love to read my article...
Previous Article Smokers better off quitting, even with the risk of weight gain
Next Article Don’t skip the carbs, Paleo diets are not as healthy as you think

Latest News

Google AI is helping EMEA universities and schools transform education
Education
Understanding the Real Value of a Trusted CMMC RPO Partnership
Understanding the Real Value of a Trusted CMMC RPO Partnership
News
Tech reviews: Finding devices that meet every need
Gadgets
Ten Reasons to Give Blogs Priority Over Social Media in 2025
Social Media

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?